Table 1c:
Patient Characteristics for Single Ventricle Patients Divided by Stage of Palliation (n=63). Pedimacs Patients, September 19, 2012 to June 30, 2017
| Baseline Characteristics | Stage 1 (n=23) |
Stage 2 (n=21) |
Stage 3 (n=19) |
p-value |
|---|---|---|---|---|
| Age (y) | 1.1 +/− 2.4 (n= 23) | 2.6 +/− 3.1 (n= 21) | 8.3 +/− 4.7 (n= 19) | <.0001 |
| Age (y) | <.0001 | |||
| < 1 | 17 (73.9) | 9 (42.9) | ||
| 1-5 | 5 (21.7) | 9 (42.9) | 8 (42.1) | |
| 6-10 | 1 (4.3) | 2 (9.5) | 7 (36.8) | |
| 11-19 | 1 (4.8) | 4 (21.1) | ||
| Female | 8 (34.8) | 10 (47.6) | 6 (31.6) | 0. 5 |
| Race | 0.3 | |||
| White | 15 (65.2) | 9 (42.9) | 9 (47.4) | |
| African American | 3 (13.0) | 5 (23.8) | 7 (36.8) | |
| Other | 5 (21.7) | 6 (23.8) | 3 (15.8) | |
| Body Surface Area (m2) | 0.3 +/− 0.2 (n= 23) | 7 (23.8) | 1.0 +/− 0.4 (n= 18) | <.0001 |
| Blood Urea Nitrogen (mg/dL) | 34.4 +/− 19.0 (n= 23) | 8 (23.8) | 28.8 +/− 21.8 (n= 19) | 0.6 |
| Sodium (mEq/L) | 141.3 +/− 5.9 (n= 23) | 9 (23.8) | 134.8 +/− 8.6 (n= 19) | 0.02 |
| Potassium (mEq/L) | 3.7 +/− 0.6 (n= 23) | 10 (23.8) | 3.8 +/− 0.6 (n= 19) | 0.8 |
| Aspartate Aminotransferase (u/L) | 91.0 +/− 114.1 (n= 21) | 11 (23.8) | 195.0 +/− 464.5 (n= 18) | 0.4 |
| Alanine Aminotransferase (u/L) | 43.3 +/− 41.2 (n= 21) | 12 (23.8) | 173.8 +/− 452.9 (n= 18) | 0.2 |
| Brain Natriuretic Peptide (pg/mL) | 910.8 +/− 713.1 (n= 4) | 13 (23.8) | 2134.2 +/− 1631.6 (n= 13) | 0.3 |
| Pro Brain Natriuretic Peptide (pg/mL) | 20320 +/− 12284 (n= 5) | 14 (23.8) | 614.0 +/− 643.5 (n= 2) | 0.1 |
| Albumin (g/dL) | 3.1 +/− 1.3 (n= 22) | 15 (23.8) | 3.5 +/− 0.4 (n= 18) | 0.5 |
| Pre-Albumin (mg/L) | 152.0 +/− 53.0 (n= 4) | 16 (23.8) | 125.2 +/− 48.0 (n= 5) | 0.3 |
| White Blood Cell Count (x103/μL) | 10.9 +/− 4.0 (n= 22) | 17 (23.8) | 10.1 +/− 3.0 (n= 19) | 0.03 |
| Hemoglobin (g/L) | 133.0 +/− 17.3 (n= 23) | 18 (23.8) | 140.0 +/− 18.1 (n= 19) | 0.5 |
| Platelet Count (x103/μL) | 155.7 +/− 103.6 (n= 22) | 19 (23.8) | 258.6 +/− 102.8 (n= 19) | 0.01 |
| INR (international units) | 1.6 +/− 0.7 (n= 18) | 20 (23.8) | 2.6 +/− 1.4 (n= 16) | 0.008 |
| Uric Acid (mg/dL) | 7.7 +/− 4.2 (n= 5) | 21 (23.8) | 7.3 +/− 1.7 (n= 3) | 1.0 |
| Lymphocyte Count (%) | 13.6 +/− 9.2 (n= 11) | 22 (23.8) | 17.7 +/− 10.0 (n= 16) | 0.2 |
| Creatinine (mg/dL) | 0.5 +/− 0.3 (n= 23) | 23 (23.8) | 0.8 +/− 0.4 (n= 19) | 0.06 |
| eGFR (mL/min/1.73m2) | 63.5 +/− 30.2 (n= 23) | 24 (23.8) | 76.6 +/− 29.7 (n= 18) | 0.1 |
| Bilirubin (mg/dL) | 4.6 +/− 6.0 (n= 22) | 25 (23.8) | 2.1 +/− 1.0 (n= 15) | 0.03 |
| Previous Cardiac Operation | 21 (91.3) | 26 (23.8) | 19 (100) | 0.2 |
| Previous ECMO | 7 (30.4) | 27 (23.8) | 0 (0.0) | 0.03 |
| Previous MCSD | 1 (4.3) | 28 (23.8) | 1 (5.3) | 0.6 |
| Patient Profile | 0.01 | |||
| 1. Critical Cardiogenic Shock | 13 (59.1) | 6 (28.6) | 4 (21.1) | |
| 2. Progressive Decline | 5 (22.7) | 14 (66.7) | 14 (73.7) | |
| 3. Stable but Inotrope Dependent | 4 (18.2) | 1 (4.8) | 1 (5.3) | |
| Pre-Implant Device Strategy | 0.2 | |||
| Bridge to Transplant - Listed | 13 (56.5) | 11 (52.4) | 13 (68.4) | |
| Bridge to Candidacy | 7 (30.4) | 5 (23.8) | 3 (15.8) | |
| Destination Therapy | 1 (4.8) | |||
| Bridge to Recovery | 3 (13.0) | 3 (14.3) | ||
| Other | 1 (4.8) | 3 (15.8) | ||
| Device Classification | 0.0006 | |||
| Implantable Continuous | 1 (4.3) | 2 (9.5) | 10 (52.6) | |
| Paracorporeal Continuous | 18 (78.3) | 10 (47.6) | 4 (21.1) | |
| Paracorporeal Pulsatile | 4 (17.4) | 7 (33.3) | 4 (21.1) | |
| Percutaneous | 2 (9.5) | 1 (5.3) | ||
| TAH | 2 (4.4) | |||
| Pre-Implant Device Type | 0. 4 | |||
| LVAD | 22 (95.7) | 21 (100) | 19 (100) | |
| BiVAD | 1 (4.3) |
eGFR = Estimated Glomerular Filtration Rate; ECMO = Extracorporeal Membrane Oxygenation; MCSD = Mechanical Circulatory Support Device; LVAD = Left Ventricular Assist Device; BiVAD = Biventricular Assist Device;